STOCK TITAN

Establishment Labs Hldgs Inc - ESTA STOCK NEWS

Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.

Overview

Establishment Labs Holdings Inc (ESTA) is a distinguished global medical technology company that designs, develops, manufactures, and markets innovative silicone-filled implants for breast aesthetics and reconstructive surgery. With a rich heritage spanning decades in the medical device industry, the company is renowned for its commitment to advanced engineering, rigorous safety protocols, and clinical research. Its technology-driven product portfolio is tailored to meet the evolving needs of both plastic surgeons and patients.

Core Business Areas

The company specializes in:

  • Product Innovation: Utilizing cutting-edge research and patented technology to develop silicone implants that offer superior biocompatibility and a natural look and feel.
  • Safety and Quality: Integrating advanced design features such as proprietary surface technologies to promote low inflammation and reduce complication rates.
  • Global Distribution: Delivering its products through direct sales channels to medical distributors, hospitals, clinics, and plastic surgery practices across Europe, Latin America, Asia-Pacific/Middle Eastern regions, and beyond.

Technological Excellence

At the heart of its operations is a commitment to technological excellence and safety. The company employs state-of-the-art manufacturing practices compliant with rigorous regulatory standards. Emphasis on design innovation, such as adaptive implant shapes that complement the natural dynamics of the human body, is evident in its portfolio. These advancements underscore the company’s focus on combining aesthetic outcomes with patient safety.

Industry Position and Significance

Establishment Labs stands as an authority in the specialized market of medical devices and aesthetics. Its long-standing experience in implant manufacturing, coupled with innovative product development, positions the company as a pivotal contributor within the medical aesthetics and reconstructive surgery sectors. The strategic focus on quality, clinical evidence, and regulatory compliance has solidified its reputation with healthcare professionals globally.

Commitment to Research and Clinical Excellence

Dedicated to advancing the field, the company supports a robust framework of clinical studies and scientific research, underpinning its product innovations with peer-reviewed evidence. This commitment reinforces its market presence and serves as a cornerstone for its sustained trustworthiness in healthcare technology.

Customer and Distribution Focus

By aligning its product development with the practical and aesthetic requirements of both surgeons and patients, the company builds strong relationships within the healthcare community. Its direct sales model and global distribution strategy ensure that high-quality products are accessible to a wide range of medical professionals, further enhancing its industry impact.

Conclusion

In summary, Establishment Labs Holdings Inc embodies a blend of pioneering technology and extensive industry experience. Its comprehensive approach to product innovation, quality assurance, and global distribution makes it a vital entity in the realm of medical devices and aesthetic surgery. Investors and industry observers can appreciate the company for its in-depth commitment to safety, its integration of technology and clinical data, and its clear operational focus on enhancing patient outcomes.

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a securities purchase agreement with institutional accredited investors to purchase common shares or pre-funded warrants. Preliminary unaudited financial results for Q4 2023 show expected revenue in the range of $31.4 million to $31.8 million, in line with previous guidance. Full-year 2023 revenue is expected to be $165.0 million to $165.4 million, with a year-end cash position of approximately $39.1 million. The company will sell two million common shares or pre-funded warrants at $25.00 per share, expecting aggregate gross proceeds of approximately $50 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery. The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. SmoothSilk® has been shown to produce the least amount of inflammation and foreign body response compared to other device surfaces. By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment. Juan José Chacón-Quirós, Founder and CEO of Establishment Labs, emphasized the company's commitment to improving women’s health and wellness, stating that real innovation leads to better patient outcomes, and Flora is setting a new standard in breast reconstruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in two investment conferences, including the 2023 Jefferies London Healthcare Conference and the Stephens Annual Investment Conference. CEO and Founder Juan José Chacón-Quirós and CFO Raj Denhoy will speak at the events, with live webcasts available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has received NMPA approval in China for Motiva® Implants, marking their entry into the second largest global market for breast aesthetics. The company expects Chinese plastic surgeons to adopt their technology as their first choice, based on their success in South Korea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
none
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) Announces Q3 2023 Financial Results: Revenue Up 0.8%, 2023 Revenue Guidance Increased to $165 Million, Loss from Operations Increases, FDA Clearance for Motiva Flora® SmoothSilk® Tissue Expander, Mia Femtech™ Clinical Study Data Released
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.18%
Tags
Rhea-AI Summary
Flora, the magnet-free and MR Conditional tissue expander, has been cleared for the U.S. market. Establishment Labs Holdings Inc. plans to announce its financial results for Q3 2023 on November 7, 2023, and will host a conference call to discuss those results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
Establishment Labs receives FDA clearance for Motiva Flora® SmoothSilk® Tissue Expander
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.25%
Tags
-
Rhea-AI Summary
Establishment Labs announces two-year clinical results of Mia Femtech and launch of Zen RFID technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags

FAQ

What is the current stock price of Establishment Labs Hldgs (ESTA)?

The current stock price of Establishment Labs Hldgs (ESTA) is $32.3 as of April 4, 2025.

What is the market cap of Establishment Labs Hldgs (ESTA)?

The market cap of Establishment Labs Hldgs (ESTA) is approximately 937.2M.

What is the primary business of Establishment Labs Holdings Inc?

The company is focused on designing, manufacturing, and marketing advanced silicone-filled implants for breast aesthetics and reconstructive surgery.

How does the company ensure the safety and quality of its products?

It integrates state-of-the-art technology and rigorous engineering protocols, reinforced by clinical research and adherence to regulatory standards.

Who are the main customers of Establishment Labs?

The company supplies its devices to plastic surgeons, hospitals, clinics, and medical distributors globally.

What distinguishes its implants from those of competitors?

Its implants incorporate innovative design features and patented surface technologies that promote biocompatibility and natural aesthetics while ensuring patient safety.

How is innovation emphasized within the company?

Innovation is central to its operations, demonstrated through continuous product development, technological advancements, and substantial clinical research backing its implant designs.

In which geographic regions does Establishment Labs operate?

The company has a global footprint, actively serving markets in Europe, Latin America, Asia-Pacific/Middle Eastern regions, and other territories.
Establishment Labs Hldgs Inc

Nasdaq:ESTA

ESTA Rankings

ESTA Stock Data

937.20M
25.48M
10.55%
104.02%
19.71%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
Costa Rica
ALAJUELA